CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
AGN-223575 Formulation A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02155543
NCT02155543Phase 1Completed
CompareCT.gov

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Allergan·interventional·Posted Jun 4, 2014·Updated Apr 12, 2016

In Brief

A Phase 1 clinical trial evaluating AGN-223575 Formulation A, AGN-223575 Formulation B, and 2 other interventions for Healthy Volunteers. Completed, enrolled 51 participants across 1 site.

Detailed Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of AGN-223575 in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 4, 2014
Enrollment StartMay 1, 2014
Primary CompletionDec 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.1 years ago

Interventions

AGN-223575 Formulation Adrug

One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.

AGN-223575 Formulation Bdrug

One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.

AGN-223575 Formulation Cdrug

One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.

AGN-223575 Vehicledrug

One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.